Partial
Mostly Aligned
Patient Risk:
Moderate
Summary
Some dosing statements (plaque psoriasis loading and 300 mg q4 weeks; PsA/AS initial 150 mg and escalation concept) align with label excerpts, but multiple claims about other indications/dosing patterns, weight-based/threshold dosing, trial outcomes (FUTURE 5), quantified infection risks, and monitoring for higher doses are either unsupported or not directly supported by the provided prescribing information excerpts.
Category Scores
Accurate Statements
For plaque psoriasis in adults, 300 mg subcutaneously at Weeks 0, 1, 2, 3, and 4 followed by 300 mg every 4 weeks thereafter (given as one 300 mg injection or two 150 mg injections).
Section 2.3: “Adults: 300 mg subcutaneously at Weeks 0, 1, 2, 3, 4 and every 4 weeks thereafter (given as one 300 mg injection or two 150 mg injections).”
For psoriatic arthritis, recommended subcutaneous dosage (150 mg) includes a loading regimen (Weeks 0–4, then every 4 weeks) and consideration of increasing to 300 mg every 4 weeks if active PsA persists.
Section 2.4: “Recommended subcutaneous dosage (150 mg): with loading (Weeks 0–4, then every 4 weeks) ... Consider increasing to 300 mg every 4 weeks if active PsA persists.”
For ankylosing spondylitis, 150 mg subcutaneously and consideration of increasing to 300 mg every 4 weeks if active disease persists.
Section 2.6: “Subcutaneous: 150 mg (with or without loading) and consider increasing to 300 mg every 4 weeks if active disease persists.”
Cosentyx is contraindicated in patients with a previous serious hypersensitivity reaction to secukinumab or excipients.
Section 4: “contraindicated in patients with a previous serious hypersensitivity reaction to secukinumab or to any excipients.”
Unsupported Statements
Cosentyx (secukinumab) begins with loading doses followed by maintenance dosing.
The label excerpts provided support loading for specific indications/regimens (e.g., plaque psoriasis; PsA loading), but the statement is too general to confirm across the entire product labeling.
For plaque psoriasis, clinicians may start Cosentyx at 300 mg for moderate-to-severe cases.
Section 1.1 supports indication (moderate to severe plaque psoriasis), but the provided dosage section does not link starting dose choice specifically to “moderate-to-severe cases.”
For plaque psoriasis, clinicians may start Cosentyx at 300 mg when body weight is over 90 kg.
Provided label excerpts for plaque psoriasis list fixed adult dosing (300 mg; some patients may accept 150 mg) and pediatric weight-based dosing, but no “>90 kg” threshold is provided for adults in the excerpts.
For psoriatic arthritis or ankylosing spondylitis, after the first month, Cosentyx dosing is every 4 weeks.
Label supports every 4 weeks dosing after loading for PsA (and AS with/without loading), but the statement is not fully confirmable for AS from the excerpt as written (“after the first month” implies a specific timeline).
For psoriatic arthritis or ankylosing spondylitis, Cosentyx dosing is 150 mg (one injection) weekly for the first month.
Label excerpt states PsA 150 mg with loading Weeks 0–4 (implies weekly during weeks 0–4), but it does not explicitly state “weekly for the first month” for AS; AS is described as 150 mg with or without loading.
For psoriatic arthritis, Cosentyx 300 mg may be used if needed for psoriasis involvement.
Label excerpt supports considering increasing to 300 mg every 4 weeks if active PsA persists, not specifically “psoriasis involvement.”
Dosing for other indications such as hidradenitis suppurativa or non-radiographic axial spondyloarthritis follows similar patterns and often starts at 300 mg.
Label excerpt for nr-axSpA subcutaneous dosing is 150 mg (with or without loading), not “often starts at 300 mg.”
Dose increase to Cosentyx 300 mg every 4 weeks is recommended if a patient on 150 mg has an inadequate response.
Label states “consider increasing… if active PsA persists” (and “if active disease persists” for AS), but does not use the phrase “inadequate response.”
For psoriatic arthritis with significant psoriasis (BSA > 10%), increasing to Cosentyx 300 mg every 4 weeks is recommended after the initial loading phase when response is inadequate.
Provided label excerpts do not specify BSA thresholds (e.g., >10%) or link dosing escalation to psoriasis BSA.
Guidelines emphasize assessing response at week 12 or later before switching or increasing dosing if clinical improvement is insufficient.
No week-12 assessment or guideline-based timing is included in the provided label excerpts.
Cosentyx labeling and clinical data do not support doses above 300 mg weekly or monthly.
The provided label excerpts do not include an explicit statement limiting to “above 300 mg weekly or monthly,” nor do they provide a comprehensive dose ceiling for all regimens.
Clinical trials such as FUTURE 5 reported no added benefit from higher doses.
The provided prescribing information excerpts provided do not include FUTURE 5-specific efficacy comparisons.
Clinical trials such as FUTURE 5 reported an increased infection risk with higher doses.
The excerpts include general infection risk (Section 5.1, 6.1) but do not provide FUTURE 5-specific comparisons or dose-group statements.
The FDA-approved maximum Cosentyx dose for adults is 300 mg every 4 weeks.
Label excerpts include HS where escalation to 300 mg every 2 weeks may be considered if inadequate response (Section 2.10). The statement conflicts with that possibility.
Patients with psoriasis and body weight over 90 kg often require 300 mg to achieve PASI 75 response rates above 80%.
Provided label excerpts do not include these PASI 75 response-rate details or a “>90 kg” linkage for adult plaque psoriasis dosing.
Response assessment for Cosentyx can be evaluated at 12 to 16 weeks using metrics such as PASI score, ASDAS, or BSA.
The provided label excerpts do not specify assessment timing (12–16 weeks) or these metrics for response evaluation.
A lack of 50% improvement using the assessed metrics prompts an increase or switch of therapy.
No such 50% rule is included in the provided label excerpts.
Higher Cosentyx doses may be used for psoriasis-dominant psoriatic arthritis.
Label excerpts support considering increase to 300 mg every 4 weeks if active PsA persists, but do not specify “psoriasis-dominant” as a criterion.
Cosentyx 150 mg may be sufficient for joint-focused psoriatic arthritis cases without skin involvement.
Label excerpts do not define joint-focused vs skin involvement criteria for dose selection.
Higher Cosentyx doses are associated with higher infection rates, including upper respiratory infections.
The excerpts indicate infection risk may increase generally, but they do not provide the specific “dose-associated” upper respiratory infection comparison.
Upper respiratory infections occurred in 14% of patients on higher doses compared with 11% on 150 mg.
No such quantified rates are present in the provided label excerpts.
Candidiasis occurred in 6% of patients on higher doses compared with 3% on 150 mg.
No such quantified rates are present in the provided label excerpts.
Higher Cosentyx doses require monitoring for IBD flares.
The provided label excerpts discuss IBD exacerbations and monitoring/ caution generally (Section 5.4) but do not state that this is specifically required due to higher doses.
Higher Cosentyx doses require monitoring for hypersensitivity.
The provided label excerpts describe hypersensitivity reactions and actions to take generally (Section 5.2) but do not specify dose-dependent hypersensitivity monitoring for “higher doses.”
There was no mortality signal in trials up to 5 years.
The provided label excerpts do not mention mortality signal assessments up to 5 years.
Contradictions
Low
AI Statement
The FDA-approved maximum Cosentyx dose for adults is 300 mg every 4 weeks.
Label Reference
Section 2.10 (Hidradenitis suppurativa): “if inadequate response, consider increasing to 300 mg every 2 weeks.”
Important Omissions
TB screening and latent TB treatment prior to initiation (and vaccination considerations) are required per labeling before starting COSENTYX.
Importance:
Moderate
IBD exacerbations: exercise caution and monitor patients with symptoms (not specifically tied to higher doses in the provided claims).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Several dosing/safety-related assertions are unsupported by the provided label excerpts (e.g., weight threshold >90 kg, FUTURE 5-specific quantified infection/candidiasis rates, monitoring claims tied to higher doses, mortality signal). One dosing ceiling claim contradicts HS labeling where 300 mg every 2 weeks may be considered.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Mostly Aligned
Primary Issue
Multiple claims are not supported by the provided prescribing information excerpts (especially trial-specific FUTURE 5 details, quantified adverse event rates, response assessment timing/rules, and weight-threshold assertions). Additionally, the statement that the adult maximum dose is 300 mg every 4 weeks contradicts HS dosing where 300 mg every 2 weeks may be considered.
Suggested Improvement
Restrict assertions to what is explicitly supported in the provided label excerpts (e.g., plaque psoriasis regimen; general infection/IBD/hypersensitivity warnings; consideration to increase to 300 mg every 4 weeks for active PsA/AS; HS escalation to 300 mg every 2 weeks if inadequate response). Remove or qualify unsupported quantitative trial and timing statements not present in the provided label text.